Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy.
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
24
12
2021
accepted:
16
05
2022
pubmed:
18
6
2022
medline:
28
9
2022
entrez:
17
6
2022
Statut:
ppublish
Résumé
Patients with cancer frequently receive immune-checkpoint inhibitors (ICIs), which may modulate immune responses to COVID-19 vaccines. Recently, cytokine release syndrome (CRS) was observed in a patient with cancer who received BTN162b2 vaccination under ICI treatment. Here, we analyzed adverse events and serum cytokines in patients with 23 different tumors undergoing (n = 64) or not undergoing (n = 26) COVID-19 vaccination under ICI therapy in a prospectively planned German single-center cohort study (n = 220). We did not observe clinically relevant CRS (≥grade 2) after vaccination (95% CI 0-5.6%; Common Terminology of Adverse Events v.5.0) in this small cohort. Within 4 weeks after vaccination, serious adverse events occurred in eight patients (12.5% 95% CI 5.6-23%): six patients were hospitalized due to events common under cancer therapy including immune related adverse events and two patients died due to conditions present before vaccination. Despite absence of CRS symptoms, a set of pairwise-correlated CRS-associated cytokines, including CXCL8 and interleukin-6 was >1.5-fold upregulated in 40% (95% CI 23.9-57.9%) of patients after vaccination. Hence, elevated cytokine levels are common and not sufficient to establish CRS diagnosis.
Identifiants
pubmed: 35715501
doi: 10.1038/s43018-022-00398-7
pii: 10.1038/s43018-022-00398-7
pmc: PMC9499865
doi:
Substances chimiques
COVID-19 Vaccines
0
Cytokines
0
Immune Checkpoint Inhibitors
0
Interleukin-6
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1039-1051Investigateurs
Christiane S Cussigh
(CS)
Katharina A Kälber
(KA)
Omar Abdelrahim
(O)
Elena Busch
(E)
Patrick Derigs
(P)
Katharina Dischinger
(K)
Fouad Mitri
(F)
Kerstin Schmidt
(K)
Irfan A Bhatti
(IA)
Barbara Grün
(B)
Nicolas Hohmann
(N)
Lena Woydack
(L)
Xin-Wen Zhang
(XW)
Dyke Ferber
(D)
Andreas Mock
(A)
Tillmann Pompecki
(T)
Timo Schank
(T)
Carlo Fremd
(C)
Georg M Haag
(GM)
Niels Halama
(N)
Romy Kirsten
(R)
Jessica C Hassel
(JC)
Dirk Jäger
(D)
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s).
Références
Russell, B. et al. Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in London. Br. J. Cancer 125, 939–947 (2021).
doi: 10.1038/s41416-021-01500-z
Trapani, D. & Curigliano, G. COVID-19 vaccines in patients with cancer. Lancet Oncol. 22, 738–739 (2021).
doi: 10.1016/S1470-2045(21)00250-3
Ribas, A. et al. Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited. Cancer Discov. 11, 233–236 (2021).
doi: 10.1158/2159-8290.CD-20-1817
Sahin, U., Karikó, K. & Türeci, Ö. mRNA-based therapeutics — developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759–780 (2014).
doi: 10.1038/nrd4278
Frenck, R.W. et al. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. New Engl. J. Med. https://doi.org/10.1056/NEJMoa2107456 (2021).
Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet 396, 467–478 (2020).
doi: 10.1016/S0140-6736(20)31604-4
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2020).
doi: 10.1056/NEJMoa2035389
Fendler, A. et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study. Nat. Cancer https://doi.org/10.1038/s43018-021-00274-w (2021).
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
doi: 10.1056/NEJMoa2034577
Haslam, A. & Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Network Open 2, e192535 (2019).
doi: 10.1001/jamanetworkopen.2019.2535
Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant. 25, 625–638 (2019).
doi: 10.1016/j.bbmt.2018.12.758
Fajgenbaum, D. C. & June, C. H. Cytokine storm. N. Engl. J. Med. 383, 2255–2273 (2020).
doi: 10.1056/NEJMra2026131
Au, L. et al. Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2. Nat. Med. https://doi.org/10.1038/s41591-021-01387-6 (2021).
Waissengrin, B., Agbarya, A., Safadi, E., Padova, H. & Wolf, I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol. 22, 581–583 (2021).
doi: 10.1016/S1470-2045(21)00155-8
Monin, L. et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 22, 765–778 (2021).
doi: 10.1016/S1470-2045(21)00213-8
Voysey, M. et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet 397, 99–111 (2021).
doi: 10.1016/S0140-6736(20)32661-1
Galván-Román, J. M. et al. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: an observational study. J. Allergy Clin. Immunol. 147, 72–80.e78 (2021).
doi: 10.1016/j.jaci.2020.09.018
Hay, K. A. et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor–modified T-cell therapy. Blood 130, 2295–2306 (2017).
doi: 10.1182/blood-2017-06-793141
Chen, L. Y. C., Hoiland, R. L., Stukas, S., Wellington, C. L. & Sekhon, M. S. Assessing the importance of interleukin-6 in COVID-19. Lancet Resp. Med. 9, e13 (2021).
doi: 10.1016/S2213-2600(20)30600-7
Morgan, C. J. Landmark analysis: a primer. J. Nucl. Cardiol. 26, 391–393 (2019).
doi: 10.1007/s12350-019-01624-z
Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107–112 (2020).
doi: 10.1038/s41586-020-2537-9
Sahin, U. et al. COVID-19 vaccine BNT162b1 elicits human antibody and T
doi: 10.1038/s41586-020-2814-7
Liang, F. et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol.Ther. 25, 2635–2647 (2017).
doi: 10.1016/j.ymthe.2017.08.006
Pelka, K. et al. Spatially organized multicellular immune hubs in human colorectal cancer. Cell https://doi.org/10.1016/j.cell.2021.08.003 (2021).
Maslov, D. V. et al. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. J. Immunother. Cancer 9, e002261 (2021).
doi: 10.1136/jitc-2020-002261
Iorgulescu, J. B. et al. Concurrent dexamethasone limits the clinical benefit of immune checkpoint blockade in glioblastoma. Clin. Cancer Res. 27, 276–287 (2021).
doi: 10.1158/1078-0432.CCR-20-2291
Valachis, A. et al. Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors. OncoImmunology 10, 1886725 (2021).
doi: 10.1080/2162402X.2021.1886725
Sun, Z. et al. A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8
doi: 10.1038/s41467-019-11782-w
Mevorach, D. et al. Myocarditis after BNT162b2 mRNA vaccine against Covid-19 in Israel. N. Engl. J. Med. 385, 2140–2149 (2021).
doi: 10.1056/NEJMoa2109730
Phillips, R., Hazell, L., Sauzet, O. & Cornelius, V. Analysis and reporting of adverse events in randomised controlled trials: a review. BMJ Open 9, e024537 (2019).
doi: 10.1136/bmjopen-2018-024537
Strobel, S.B., Machiraju, D., Kälber, K.A. & Hassel, J.C. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment. Cancer Immunol. Immunother. https://doi.org/10.1007/s00262-021-03133-w (2021).
Moore, H. M. et al. Biospecimen reporting for improved study quality (BRISQ). Cancer Cytopathol. 119, 92–102 (2011).
doi: 10.1002/cncy.20147
Miroglio, B., Zeber, D., Kaye, J. & Weiss, R. The effect of ad blocking on user engagement with the web. In: Proc. 2018 World Wide Web Conference 813–821 (International World Wide Web Conferences Steering Committee, Lyon, France, 2018).
Walle, T. Wallet-maker/ANTICIPATE_COVID-19. Zenodo https://zenodo.org/record/6544522#.YoYUQXXMLcs (2022).